Biotech · Public company · Los Angeles, CA, US

Puma Biotechnology, Inc.

Ticker PBYI · SEC CIK 0001401667

Track this companyFree. Adds Puma Biotechnology, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials259 recruiting or active

Pipeline programs18From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline18

capecitabinePhase 3 · HER2+ Metastatic Breast Cancer (MBC)ClinicalTrials.gov · fetched Nov 12, 2026
lapatinibPhase 3 · HER2+ Metastatic Breast Cancer (MBC)ClinicalTrials.gov · fetched Nov 12, 2026
neratinibPhase 3 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
neratinibPhase 3 · HER2+ Metastatic Breast Cancer (MBC)ClinicalTrials.gov · fetched Nov 12, 2026
AlisertibPhase 2 · Hormone Receptor Positive HER-2 Negative Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
AlisertibPhase 2 · Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
AlisertibPhase 2 · Small Cell Lung Cancer ( SCLC )ClinicalTrials.gov · fetched Nov 12, 2026
BudesonidePhase 2 · Early Stage HER2+ Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
ColestipolPhase 2 · Early Stage HER2+ Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
Endocrine therapyPhase 2 · Hormone Receptor Positive HER-2 Negative Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
FulvestrantPhase 2 · Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 MutationsClinicalTrials.gov · fetched Nov 12, 2026
LoperamidePhase 2 · Early Stage HER2+ Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
NeratinibPhase 2 · Early Stage HER2+ Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
NeratinibPhase 2 · Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 MutationsClinicalTrials.gov · fetched Nov 12, 2026
PaclitaxelPhase 2 · Small Cell Lung Cancer ( SCLC )ClinicalTrials.gov · fetched Nov 12, 2026
PaclitaxelPhase 2 · Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 MutationsClinicalTrials.gov · fetched Nov 12, 2026
TrastuzumabPhase 2 · Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 MutationsClinicalTrials.gov · fetched Nov 12, 2026
Almac HER-Seq AssayHormone Receptor-Positive, HER2-Negative Metastatic Breast CancerClinicalTrials.gov · fetched Nov 12, 2026

Clinical trials25

A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)PHASE2 · RECRUITING · started Sep 17, 2026ClinicalTrials.gov NCT07465757 · fetched Nov 12, 2026
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast CancerPHASE2 · RECRUITING · started Nov 19, 2024ClinicalTrials.gov NCT06369285 · fetched Nov 12, 2026
Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast CancersPHASE2 · RECRUITING · started Jun 11, 2024ClinicalTrials.gov NCT05919108 · fetched Nov 12, 2026
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung CancerPHASE2 · RECRUITING · started Feb 8, 2024ClinicalTrials.gov NCT06095505 · fetched Nov 12, 2026
Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal CancerPHASE2 · ACTIVE_NOT_RECRUITING · started Jan 12, 2024ClinicalTrials.gov NCT06109467 · fetched Nov 12, 2026
Fulvestrant + Neratinib In Breast CancerPHASE2 · WITHDRAWN · started Jul 1, 2023ClinicalTrials.gov NCT04901299 · fetched Nov 12, 2026
Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis TestPHASE1_PHASE2 · TERMINATED · started Aug 18, 2022ClinicalTrials.gov NCT05243641 · fetched Nov 12, 2026
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast CancersPHASE2 · RECRUITING · started Jul 21, 2022ClinicalTrials.gov NCT04886531 · fetched Nov 12, 2026
Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer PatientsPHASE1 · RECRUITING · started Jun 24, 2022ClinicalTrials.gov NCT05274048 · fetched Nov 12, 2026
Neratinib in Patients With Metastatic Castration-Resistant Prostate CancerPHASE2 · WITHDRAWN · started May 21, 2021ClinicalTrials.gov NCT04781374 · fetched Nov 12, 2026
Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian CancerPHASE1 · ACTIVE_NOT_RECRUITING · started Aug 24, 2020ClinicalTrials.gov NCT04502602 · fetched Nov 12, 2026
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung CancerPHASE1 · COMPLETED · started Nov 12, 2019ClinicalTrials.gov NCT04085315 · fetched Nov 12, 2026
Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative BreastPHASE2 · UNKNOWN · started Jun 21, 2019ClinicalTrials.gov NCT03812393 · fetched Nov 12, 2026
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated CaPHASE1_PHASE2 · SUSPENDED · started May 1, 2019ClinicalTrials.gov NCT03919292 · fetched Nov 12, 2026
HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of NeratinibTERMINATED · started Mar 14, 2019ClinicalTrials.gov NCT03786107 · fetched Nov 12, 2026
Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and NeratinibPHASE2 · COMPLETED · started Oct 9, 2018ClinicalTrials.gov NCT03094052 · fetched Nov 12, 2026
Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast CancerPHASE1_PHASE2 · COMPLETED · started Dec 13, 2017ClinicalTrials.gov NCT03377387 · fetched Nov 12, 2026
Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast CancerPHASE2 · TERMINATED · started Oct 25, 2017ClinicalTrials.gov NCT03289039 · fetched Nov 12, 2026
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)PHASE2 · RECRUITING · started Feb 9, 2017ClinicalTrials.gov NCT02977780 · fetched Nov 12, 2026
An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and LoperamidePHASE2 · COMPLETED · started Feb 1, 2015ClinicalTrials.gov NCT02400476 · fetched Nov 12, 2026
Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 MutationsPHASE2 · TERMINATED · started Sep 30, 2013ClinicalTrials.gov NCT01953926 · fetched Nov 12, 2026
A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic SettingPHASE3 · COMPLETED · started Mar 29, 2013ClinicalTrials.gov NCT01808573 · fetched Nov 12, 2026
Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast CancerPHASE2 · COMPLETED · started Dec 11, 2012ClinicalTrials.gov NCT01670877 · fetched Nov 12, 2026
HKI-272 for HER2-Positive Breast Cancer and Brain MetastasesPHASE2 · COMPLETED · started Feb 1, 2012ClinicalTrials.gov NCT01494662 · fetched Nov 12, 2026
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast CancerPHASE3 · COMPLETED · started Jul 9, 2009ClinicalTrials.gov NCT00878709 · fetched Nov 12, 2026

SEC filings12

10-Q · FORM 10-QSEC EDGAR · filed Nov 9, 2026 · fetched Nov 12, 2026
8-K · FORM 8-KSEC EDGAR · filed Nov 5, 2026 · fetched Nov 12, 2026
10-Q · FORM 10-QSEC EDGAR · filed Aug 6, 2026 · fetched Nov 12, 2026
8-K · FORM 8-KSEC EDGAR · filed Aug 6, 2026 · fetched Nov 12, 2026
8-K · FORM 8-KSEC EDGAR · filed Jun 16, 2026 · fetched Nov 12, 2026
10-Q · FORM 10-QSEC EDGAR · filed May 7, 2026 · fetched Nov 12, 2026
8-K · FORM 8-KSEC EDGAR · filed May 7, 2026 · fetched Nov 12, 2026
10-K · FORM 10-KSEC EDGAR · filed Feb 26, 2026 · fetched Nov 12, 2026
8-K · FORM 8-KSEC EDGAR · filed Feb 26, 2026 · fetched Nov 12, 2026
10-Q · FORM 10-QSEC EDGAR · filed Nov 6, 2025 · fetched Nov 12, 2026
8-K · FORM 8-KSEC EDGAR · filed Nov 6, 2025 · fetched Nov 12, 2026
10-Q · FORM 10-QSEC EDGAR · filed Aug 7, 2025 · fetched Nov 12, 2026